| 956 |
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease The Lacunar Interv
|
2023-05-30 |
338 |
| 955 |
Five-Year Stroke Risk and Its Predictors in Asymptomatic Moyamoya Disease: Asymptomatic Moyamoya Registry (AMORE)
|
2023-05-30 |
281 |
| 954 |
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
|
2023-05-30 |
334 |
| 953 |
Trial of Endovascular Thrombectomy for Large Ischemic Strokes
|
2023-04-26 |
342 |
| 952 |
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patie
|
2023-04-26 |
299 |
| 951 |
Plasma Inflammatory Biomarkers Are Associated With Poststroke Cognitive Impairment: The Nor-COAST Study
|
2023-04-26 |
273 |
| 950 |
Dissociable Contributions of Thalamic-Subregions to Cognitive Impairment in Small Vessel Disease
|
2023-03-30 |
334 |
| 949 |
Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and M
|
2023-03-30 |
311 |
| 948 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Pr
|
2023-03-30 |
339 |
| 947 |
A Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage
|
2023-02-27 |
369 |
| 946 |
Stroke Lesion Volume and Injury to Motor Cortex Output Determines Extent of Contralesional Motor Cortex Reorganization
|
2023-02-27 |
314 |
| 945 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial
|
2023-02-27 |
473 |
| 944 |
Assessing Brain Tissue Viability on Nonenhanced Computed Tomography After Ischemic Stroke
|
2023-01-31 |
391 |
| 943 |
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion
|
2023-01-31 |
336 |
| 942 |
Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AF
|
2023-01-31 |
333 |
HOME
LOGIN
